Celldex Therapeutics, Inc.
General ticker "CLDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Celldex Therapeutics, Inc. follows the US Stock Market performance with the rate: 55.5%.
Estimated limits based on current volatility of 1.6%: low 39.10$, high 40.35$
Factors to consider:
- Total employees count: 186 (+16.2%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Need for additional capital, Regulatory and compliance, Clinical trial failure, Market competition, Manufacturing supply issues
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.21$, 38.42$]
- 2026-12-31 to 2027-12-31 estimated range: [13.69$, 33.31$]
Financial Metrics affecting the CLDX estimates:
- Negative: with PPE of -6.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.89 <= 0.28
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 90.43 > 63.63
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 11.79 > -0.64
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CLDX quotes
Long-term CLDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6.88MM | $7.02MM | $1.54MM |
| Operating Expenses | $161.43MM | $202.10MM | $288.91MM |
| Operating Income | $-154.54MM | $-195.08MM | $-287.37MM |
| Non-Operating Income | $13.11MM | $37.22MM | $28.61MM |
| R&D Expense | $118.01MM | $163.55MM | $245.07MM |
| Income(Loss) | $-141.43MM | $-157.86MM | $-258.76MM |
| Net Income(Loss)* | $-141.43MM | $-157.86MM | $-258.80MM |
| Stockholders Equity | $429.17MM | $747.00MM | $527.16MM |
| Assets | $465.63MM | $792.34MM | $582.98MM |
| Operating Cash Flow | $-107.29MM | $-157.78MM | $-210.94MM |
| Capital expenditure | $1.82MM | $1.92MM | $2.71MM |
| Investing Cash Flow | $-105.78MM | $-290.13MM | $209.07MM |
| Financing Cash Flow | $218.46MM | $441.45MM | $2.39MM |
| Earnings Per Share** | $-2.92 | $-2.45 | $-3.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.